EP3953327 - MELANOCORTIN-4 RECEPTOR AGONISTS [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 24.11.2023 Database last updated on 02.09.2024 | |
Former | Grant of patent is intended Status updated on 05.07.2023 | ||
Former | Request for examination was made Status updated on 14.01.2022 | ||
Former | The international publication has been made Status updated on 14.05.2021 | Most recent event Tooltip | 12.07.2024 | Lapse of the patent in a contracting state New state(s): SM | published on 14.08.2024 [2024/33] | Applicant(s) | For all designated states LG CHEM, LTD. 128, Yeoui-daero Yeongdeungpo-gu Seoul 07336 / KR | [2022/07] | Inventor(s) | 01 /
KANG, Seung Wan E8 Block LG Science Park, 30, Magokjungang 10-ro Gangseo-gu Seoul 07796 / KR | 02 /
PARK, Hee Dong E8 Block LG Science Park, 30, Magokjungang 10-ro Gangseo-gu Seoul 07796 / KR | 03 /
PARK, Hee Dong E8 Block LG Science Park, 30, Magokjungang 10-ro Gangseo-gu Seoul 07796 / KR | 04 /
YEO, Su Jin E8 Block LG Science Park, 30, Magokjungang 10-ro Gangseo-gu Seoul 07796 / KR | 05 /
PARK, Hyun Seo E8 Block LG Science Park, 30, Magokjungang 10-ro Gangseo-gu Seoul 07796 / KR | 06 /
HONG, Ji Ho E8 Block LG Science Park, 30, Magokjungang 10-ro Gangseo-gu Seoul 07796 / KR | 07 /
AHN, Hye Won E8 Block LG Science Park, 30, Magokjungang 10-ro Gangseo-gu Seoul 07796 / KR | 08 /
CHOI, Eun Sil E8 Block LG Science Park, 30, Magokjungang 10-ro Gangseo-gu Seoul 07796 / KR | [2022/07] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2022/07] | Application number, filing date | 20885384.6 | 06.11.2020 | [2022/07] | WO2020KR15462 | Priority number, date | KR20190141649 | 07.11.2019 Original published format: KR 20190141649 | [2022/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021091283 | Date: | 14.05.2021 | Language: | EN | [2021/19] | Type: | A1 Application with search report | No.: | EP3953327 | Date: | 16.02.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.05.2021 takes the place of the publication of the European patent application. | [2022/07] | Type: | B1 Patent specification | No.: | EP3953327 | Date: | 27.12.2023 | Language: | EN | [2023/52] | Search report(s) | International search report - published on: | KR | 14.05.2021 | (Supplementary) European search report - dispatched on: | EP | 27.05.2022 | Classification | IPC: | C07D207/16, A61K31/5377, A61P3/04 | [2022/07] | CPC: |
A61P3/10 (EP,CN,IL);
A61K31/5377 (IL,KR);
C07D207/16 (EP,CN,IL,KR);
C07D413/14 (US);
A61P15/10 (EP,CN,IL);
A61P29/00 (EP,CN,IL);
A61P3/04 (EP,CN,IL,KR,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/07] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | MELANOCORTIN-4-REZEPTOR-AGONISTEN | [2022/07] | English: | MELANOCORTIN-4 RECEPTOR AGONISTS | [2022/07] | French: | AGONISTES DU RÉCEPTEUR DE LA MÉLANOCORTINE-4 | [2022/07] | Entry into regional phase | 11.11.2021 | National basic fee paid | 11.11.2021 | Search fee paid | 11.11.2021 | Designation fee(s) paid | 11.11.2021 | Examination fee paid | Examination procedure | 11.11.2021 | Examination requested [2022/07] | 14.12.2022 | Amendment by applicant (claims and/or description) | 06.07.2023 | Communication of intention to grant the patent | 14.11.2023 | Fee for grant paid | 14.11.2023 | Fee for publishing/printing paid | 14.11.2023 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 28.11.2022 | Renewal fee patent year 03 | 22.11.2023 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HR | 27.12.2023 | LT | 27.12.2023 | LV | 27.12.2023 | RS | 27.12.2023 | SM | 27.12.2023 | BG | 27.03.2024 | IS | 27.04.2024 | [2024/33] |
Former [2024/32] | HR | 27.12.2023 | |
LT | 27.12.2023 | ||
LV | 27.12.2023 | ||
RS | 27.12.2023 | ||
BG | 27.03.2024 | ||
IS | 27.04.2024 | ||
Former [2024/27] | HR | 27.12.2023 | |
LT | 27.12.2023 | ||
LV | 27.12.2023 | ||
RS | 27.12.2023 | ||
BG | 27.03.2024 | ||
Former [2024/21] | LT | 27.12.2023 | |
BG | 27.03.2024 | Documents cited: | Search | [AD]WO2008007930 (LG LIFE SCIENCES LTD [KR], et al); | [E]WO2022092914 (LG CHEMICAL LTD [KR]) | International search | [A]WO0170708 (MERCK & CO INC [US], et al); | [A]US2004019094 (LUNDSTEDT TORBJORN [SE], et al); | [A]WO2005047251 (LG LIFE SCIENCES LTD [KR], et al); | [DA]WO2008007930 (LG LIFE SCIENCES LTD [KR], et al); | [DA]WO2010056022 (LG LIFE SCIENCES LTD [KR]) | by applicant | WO2004092126 | WO2008007930 | WO2010056022 |